+126.3%
VXUS vs MRNA
+554.4%
-428.1%
-34.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.0% | +5.4% | -4.4% | +0.8% |
| 7D | -1.4% | -1.1% | -0.4% | -1.4% |
| 30D | -0.5% | +126.1% | -126.6% | -5.5% |
| 3M | +2.6% | +190.0% | -187.5% | -4.1% |
| 6M | +10.9% | +157.2% | -146.4% | +4.1% |
| YTD | +16.1% | +388.2% | -372.1% | +5.4% |
| 1Y | +22.3% | +467.0% | -444.8% | +9.8% |
| 3Y | +72.0% | +36.1% | +35.9% | +61.8% |
| 5Y | +54.1% | -68.0% | +122.1% | +47.4% |
| All | +126.3% | +554.4% | -428.1% | +106.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling